Last updated: February 24, 2026
What Is NDC: 00069-3060?
NDC: 00069-3060 refers to a specific pharmaceutical product listed in the National Drug Code system. According to FDA records, this code corresponds to Dextromethorphan HBr (dextromethorphan hydrobromide) 20 mg in a liquid syrups form.
Market Landscape Overview
Current Market Size
Dextromethorphan (DXM) is a widely used cough suppressant available over-the-counter (OTC) and in prescription formulations, although NDC 00069-3060 is an OTC product. The U.S. OTC cough and cold market is valued at approximately $2 billion annually[1]. Dextromethorphan accounts for roughly 25% of this segment, primarily driven by consumer demand for non-opioid cough suppressants.
Competitive Landscape
Major brands utilising dexromethorphan include:
- Robitussin DM
- Delsym (12-hour formulation)
- Vicks Formula 44
Generic variants are prevalent, with discount pharmacies offering lower-cost versions. Market share concentration is moderate, with the top three brands controlling roughly 60% of sales[2].
Supply Chain Dynamics
Production involves extraction and synthesis of dexromethorphan, a complex chemical synthesis process. Raw material availability influences pricing. Over-the-counter sales are generally subject to minimal regulation and inventory is maintained across retail and wholesale outlets.
Regulatory Status
The product is classified as OTC, with formulation and labeling governed by the FDA’s monograph for cough and cold products. No current indications for prescription use; no recent FDA safety alerts or reformulation requirements noted.
Price Trends and Projections
Historical Pricing Data
- Average wholesale price (AWP): $0.05 per mL in 2020
- Consumer retail price: $0.10 per mL in 2022
- Unit cost for manufacturers: Approx. $0.02–$0.03 per mL
Factors Influencing Prices
- Raw Material Costs: Fluctuate with supply chain disruptions; recent shortages raised wholesale costs by 10%.
- Regulatory Changes: Stricter testing provisions could increase manufacturing costs by 15% over the next two years.
- Market Competition: Entry of lower-cost generics suppresses retail prices.
- Consumer Demand: Continues steady due to seasonal cough and cold prevalence, especially in winter months.
Price Projections (2023–2028)
| Year |
Wholesale Price (per mL) |
Retail Price (per mL) |
Assumed Key Drivers |
| 2023 |
$0.055 |
$0.11 |
Stable raw material costs |
| 2024 |
$0.057 |
$0.12 |
Slight increase in production costs |
| 2025 |
$0.058 |
$0.12–$0.13 |
Market saturation and price competition |
| 2026 |
$0.060 |
$0.13 |
Potential regulatory adjustments |
| 2027 |
$0.062 |
$0.14 |
Increased raw material costs |
| 2028 |
$0.065 |
$0.14–$0.15 |
Possible reformulation or quality standards shifts |
Prices are approximations based on current market trends and projected costs.
Market Drivers and Risks
Drivers:
- Seasonality of cough and cold ailments.
- Growing preference for non-opioid medications.
- Consumer shifts favoring generic products.
Risks:
- Regulatory actions targeting abuse potential (dextromethorphan has abuse concerns).
- New formulations or formulations with added ingredients may alter market share.
- Supply chain disruptions affecting raw material prices.
Strategic Implications
- Generic producers can expand market share by undercutting branded prices, especially in discount segments.
- Pharmaceutical companies may explore reformulation to enhance efficacy or abuse-deterrent features.
- Investors should monitor raw material costs and regulatory shifts as potential market destabilizers.
Key Takeaways
- NDC: 00069-3060 corresponds to an OTC dextromethorphan liquid.
- Market size for OTC cough syrups approximates $2 billion annually in the U.S.
- Competition is intense with multiple generics; prices remain low but are subject to incremental increases.
- Price projections suggest a gradual rise over the next five years, influenced by raw material costs and regulatory factors.
- Risks include potential regulatory restrictions and market saturation.
FAQs
1. How is the demand for dextromethorphan expected to change?
Demand remains steady during cold and flu seasons, with potential slight growth driven by expanding OTC availability and consumer preference for non-opioid options.
2. Which factors could significantly impact the price of this product?
Raw material shortages, regulatory changes, and new formulations can increase manufacturing costs and influence retail prices.
3. Are there regulatory threats to dextromethorphan products?
Yes. Abuse potential has led to scrutiny and potential legislative actions; some jurisdictions consider restricting sales or adding tamper-deterrent features.
4. How does the competitive landscape impact pricing?
High generic penetration maintains low prices; brand-name products retain a premium, but price competition constrains overall profit margins.
5. What investment opportunities exist within this market?
Opportunities lie in developing abuse-deterrent formulations, expanding generic production, and innovating combination products to capture additional market segments.
References
[1] IBISWorld. (2022). OTC Cold & Cough Medicine in the US.
[2] MarketResearch.com. (2022). OTC cough and cold market share analysis.
[3] FDA. (2022). OTC Monograph: Cough, Cold, and Allergy Products.
[4] IQVIA. (2021). U.S. Prescription and OTC Product Trends.
